Company Growth (employees)
Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, US
Key People/Management at Nektar Therapeutics
Robert Chess
Chairman of the Board
Jillian Thomsen
Senior Vice President, Finance and Chief Accounting Officer
Dorian Hirth
Senior Vice President, Human Resources and Facilities Operations
Timothy Riley
Senior Vice President, Technology Assessment and Quality Assurance
Nektar Therapeutics Office Locations
Nektar Therapeutics has offices in San Francisco, Huntsville and Hyderabad
San Francisco, US (HQ)
455 Mission Bay Boulevard South
Hyderabad, IN
Sy.Nos.101/2 Genome Valley Lalgadi Malakpet Shameerpet Mandal Rangareddy District Hyderabad
Huntsville, US
1112 Church Street
Nektar Therapeutics Financials and Metrics
Nektar Therapeutics Financials
Nektar Therapeutics's revenue was reported to be $24.7 m in Q1, 2017
USD
Revenue (Q1, 2017) | 24.7 m |
Gross profit (Q1, 2017) | 18.6 m |
Gross profit margin (Q1, 2017), % | 75% |
Net income (Q1, 2017) | (63.9 m) |
EBIT (Q1, 2017) | (54.4 m) |
Market capitalization (20-Oct-2017) | 3.8 b |
Cash (31-Mar-2017) | 23.5 m |
Nektar Therapeutics's current market capitalization is $3.8 b.
| USD | FY, 2013 | FY, 2014 | Y, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 148.9 m | 200.7 m | 230.8 m | 165.4 m |
Revenue growth, % | 35% | 15% | (28%) | |
Cost of goods sold | 38.5 m | 28.5 m | 34.1 m | 30.2 m |
Gross profit | 110.4 m | 172.2 m | 196.7 m | 135.2 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 28.5 m | 132.9 m | 108.8 m | 22.7 m | 60 m | 58.9 m | 32.8 m | 36.3 m | 24.7 m |
Cost of goods sold | 5.1 m | 9.2 m | 8.4 m | 10.5 m | 6.8 m | 8.9 m | 7.7 m | 7 m | 6.1 m |
Gross profit | 23.4 m | 123.7 m | 100.4 m | 12.1 m | 53.2 m | 50 m | 25.1 m | 29.3 m | 18.6 m |
Gross profit Margin, % | 82% | 93% | 92% | 54% | 89% | 85% | 76% | 81% | 75% |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 39.1 m | 12.4 m | 55.6 m | 59.6 m |
Inventories | 13.5 m | 13 m | 11.3 m | 11.1 m |
Current Assets | 257.9 m | 288.2 m | 350.1 m | 426.3 m |
PP&E | 67 m | 70.4 m | 71.3 m | 65.6 m |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Cash | 30.7 m | 32 m | 129.5 m | 20.9 m | 18.8 m | 72.5 m | 55.7 m | 63.3 m | 23.5 m |
Accounts Receivable | 3 m | 46.1 m | 2.9 m | 3.7 m | 3 m | 39.7 m | 27.8 m | 14.2 m | 1.6 m |
Inventories | 14.1 m | 11.7 m | 12.5 m | 10.1 m | 10.4 m | 11.3 m | 10.3 m | 10.8 m | 13 m |
Current Assets | 298.2 m | 324.1 m | 347.3 m | 302.2 m | 286.4 m | 344.8 m | 318.3 m | 282.5 m | 381 m |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (162 m) | (53.9 m) | (81.2 m) | (153.5 m) |
Depreciation and Amortization | 14.3 m | 12.9 m | 12.9 m | 15.4 m |
Accounts Receivable | 3.6 m | (1.4 m) | (16 m) | 4.3 m |
Inventories | 4.8 m | 500 k | 1.6 m | 237 k |
| USD | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (32.6 m) | 70.6 m | 33.8 m | (52.7 m) | (8.2 m) | (19.5 m) | (48.6 m) | (43.2 m) | (63.9 m) |
Depreciation and Amortization | 3 m | ||||||||
Accounts Receivable | 3 m | 46.1 m | 722 k | 3.7 m | 3 m | 39.7 m | 27.8 m | 14.2 m | 1.6 m |
Inventories | 14.1 m | 11.7 m | 441 k | 10.1 m | 10.4 m | 11.3 m | 10.3 m | 10.8 m | 13 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 52.8 k |
Financial Leverage | 11.8 x |
